authors
- Coleman, RE
- Rosen, LS
- Gordon, D
- Major, Pierre
- Kaminski, M
- Apffelstaedt, J
- Howell, A
- Chen, BL
- Seaman, JJ
Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis.
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- December 1, 2002
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
presented at event
- 25th San Antonio Breast Cancer Symposium Conference